Introduction

More than 1 million cases of heart failure are diagnosed each year. Heart failure is the single most frequent cause of hospitalization among the elderly. Annual costs exceed $24,000 per patient and may total $70 billion by 2030. Cognitive decline is an important comorbidity of heart failure. Symptoms of cognitive decline can decrease patient compliance with treatment plans and increase the risk of hospitalization. Addressing cognitive decline in the management of heart failure is a component of current clinical practice guidelines. A pilot study randomized patients with cognitive decline due to heart failure into three groups; the training program BrainHQ, puzzles, and usual care. Costs were lower for patients in the BrainHQ group, but the difference was not statistically significant. A larger scale trial included three ways of measuring costs; electronic medical records (EMR), the Medical Resource Utilization Questionnaire (MRUQ) and the Living with Heart Failure Questionnaire (LHFQ). 

Research Question

Do alternative cost measures yield similar results? Additionally, does the choice of cost measure affect the conclusions drawn about the cost of treatment for patients with cognitive decline due to heart failure?

Methods

This study used disaggregated patient data from the recently completed larger trial. Costs of medical services were compared across the cost measures and treatment groups. Stata SE 17 was used to perform Poisson regression analysis on the difference in counts.

Hospitalizations

![Figure 2. Reported Number of Hospitalizations by Survey Method. There were no statistically significant differences in number of hospitalizations between the survey methods. The MRUQ reported the fewest hospitalizations.]

<table>
<thead>
<tr>
<th>Number of Hospitalizations</th>
<th>Number of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-5</td>
<td>0.127</td>
</tr>
<tr>
<td>6-15</td>
<td>0.218</td>
</tr>
<tr>
<td>16-20</td>
<td>0.127</td>
</tr>
<tr>
<td>21-47</td>
<td>0.218</td>
</tr>
</tbody>
</table>

Key Results

![Figure 5. Mean Number of Hospitalizations per Patient by Treatment Group Measured by Survey Method. P-values taken from Poisson regression at difference from Brain HQ. MRUQ reported a significant difference, p=0.026. Only the difference between BrainHQ and Usual Care when measured with MRUQ is statistically significant.]

Conclusion

Alternative cost measures do not yield similar results in the counts of use of medical services by patients with cognitive decline due to heart failure. Electronic medical records report use of more services than some patient reported questionnaires. The choice of cost measure does affect the conclusions drawn about the cost-effectiveness of treatment for patients with cognitive decline due to heart failure. Only analysis using the Medical Resource Utilization Questionnaire suggests significant differences in costs among treatment groups.

References